UK markets closed

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.87-0.08 (-0.89%)
At close: 04:00PM EDT
8.87 0.00 (0.00%)
After hours: 04:00PM EDT

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom

Full-time employees76

Key executives

NameTitlePayExercisedYear born
Dr. Saurabh Saha M.D., Ph.D.CEO & Director1.04MN/A1976
Dr. David M. Chao Ph.D.Chief Administrative Officer710.3kN/A1968
Dr. Antoine Yver M.D., M.Sc.Executive VP & Chairman of Development773.14kN/A1958
Dr. Gregory M. Weinhoff M.B.A., M.D.Principal Accounting Officer & CFO655kN/A1971
Ms. Tia L. BushChief Technology & Quality OfficerN/AN/A1971
Ms. Kristen K. Sheppard Esq., J.D.Senior Vice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Iqbal J. Hussain L.L.B.General Counsel, Chief Compliance Officer & Corporate SecretaryN/AN/A1981
Ms. Karen M. AndersonChief People OfficerN/AN/A1968
Dr. Harris L. Rotman Ph.D.Senior Vice President of Regulatory AffairsN/AN/AN/A
Dr. Patrick Yue M.D.Senior VP of Clinical Development & Innovative MedicinesN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Corporate governance

Centessa Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.